-
In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, marking a reclassification of the stock within major index families.
-
This shift signals that index providers now view Bristol-Myers Squibb more as a defensive, income-oriented holding than a growth-driven pharmaceutical name, aligning with its dividend profile and efforts to manage patent expirations.
-
Next, we will examine how Bristol-Myers Squibb’s move into value and defensive indices affects its existing investment narrative and risk balance.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
Bristol-Myers Squibb Investment Narrative Recap
To own Bristol-Myers Squibb today, you need to believe that its pipeline, recent launches, and partnerships can offset mounting patent risks while the company continues to support its dividend. The June 2026 shift from Russell growth benchmarks into value and defensive indices does not materially alter the near term story: the key catalyst remains execution on new products, while the biggest risk is how quickly revenues and margins are pressured as major drugs lose exclusivity.
Against that backdrop, the company’s steady dividend profile looks especially relevant. In June 2026, Bristol-Myers Squibb’s board reaffirmed a quarterly dividend of US$0.63 per share, extending a 17 year streak of annual increases. That income focus fits the new value defensive index placement and highlights how much of the near term appeal rests on reliable cash returns while investors watch whether newer therapies like Sotyktu, Camzyos, and expanded Opdivo indications can reshape the growth story.
Yet beneath the defensive label, investors should be aware that patent cliffs and pricing pressure could still unsettle what looks like a stable income story…
Read the full narrative on Bristol-Myers Squibb (it’s free!)
Bristol-Myers Squibb’s narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This requires a 6.2% yearly revenue decline and an earnings increase of about $1.3 billion from $7.3 billion today.
Uncover how Bristol-Myers Squibb’s forecasts yield a $62.96 fair value, a 9% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already cautious, projecting revenues at about US$37.4 billion and earnings near US$8.1 billion by 2029, so you should expect that Bristol-Myers Squibb’s reclassification into value defensive indices might push these already pessimistic views on patent cliffs and pricing pressure even further, and it is worth comparing those assumptions with more optimistic takes before deciding where you stand.